Pulmonary nodules and immunotherapy: disease progression or toxicity of anti-PD1/anti-PDL1 checkpoint inhibitors?
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference7 articles.
1. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination;Boutros;Nat Rev Clin Oncol,2016
2. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis;Chuzi;Canc Manag Res,2017
3. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients;Delaunay;Eur Respir J,2017
4. Organising pneumonia;Cordier;Thorax,2000
5. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy;Naidoo;J Clin Oncol Off J Am Soc Clin Oncol,2016
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Radiographic features of pneumonitis in patients treated with immunotherapy compared to traditional chemotherapy for non-small cell lung cancer;Clinical Imaging;2023-01
2. Treatment after progression in the era of immunotherapy;The Lancet Oncology;2020-10
3. Difficulties in differentiating between checkpoint inhibitor pneumonitis and lung metastasis in a patient with melanoma;Immunotherapy;2020-04
4. Persistent anti-tumor response in cancer patients experiencing pneumonitis related to immune checkpoint blockade;Acta Clinica Belgica;2019-09-07
5. Pembrolizumab;Reactions Weekly;2018-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3